Transdermal is better than oral: Observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with Rivastigmine

Dementia and Geriatric Cognitive Disorders

Volumn 35, Issue 1-2, 2013, Pages 23-33

  Boada, Mercè ^a,b   Arranz, Francisco Javier ^c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c ESTEVE   (Spain)

Author keywords

Acetylcholinesterase inhibitors; Caregiver burden; Medication adherence; Patient preferences

Indexed keywords

ATORVASTATIN; DONEPEZIL; ENALAPRIL; GALANTAMINE; MEMANTINE; METFORMIN; OMEPRAZOLE; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CAREGIVER; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; DEMENTIA; FEMALE; GERIATRICIAN; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; MORISKY GREEN QUESTIONNAIRE; MULTICENTER STUDY; NEUROLOGIST; NURSING HOME; OBSERVATIONAL STUDY; OPEN STUDY; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; PROCEDURES; QUESTIONNAIRE; RECOMMENDED DRUG DOSE; SATISFACTION; SCORING SYSTEM; TREATMENT SATISFACTION WITH MEDICINE;

EID: 84872056061     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000345989     Document Type: Article

References (42)

1. Ziegler-Graham K, Brookmeyer R, Johnson E, Arrighi HM: Worldwide variation in the doubling time of Alzheimer's disease incidence rates. Alzheimers Dement 2008; 4: 316-323.
2. Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P: EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 2010; 17: 1236-1248.
3. Connell CM, Janevic MR, Gallant MP: The costs of caring: impact of dementia on family caregivers. J Geriatr Psychiatry Neurol 2001; 14: 179-187.
4. Mayeux R: Clinical practice. Early Alzheimer's disease. N Engl J Med 2010; 362: 2194-2201.
5. Olazaran J, Reisberg B, Clare L, Cruz I, Pena-Casanova J, Del Ser T, Woods B, Beck C, Auer S, Lai C, Spector A, Fazio S, Bond J, Kivipelto M, Brodaty H, Rojo JM, Collins H, Teri L, Mittelman M, Orrell M, Feldman HH, Muniz R: Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy. Dement Geriatr Cogn Disord 2010; 30: 161-178.
6. Winblad B, Jelic V: Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Dis Assoc Disord 2004; 18(suppl 1):S2-S8.
7. Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS: Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther 2009; 1: 7.
8. Luppa M, Luck T, Brähler E, König HH, Riedel-Heller SG: Prediction of institutionalisation in dementia. Dement Geriatr Cogn Disord 2008; 26: 65-78.
9. Roe CM, Anderson MJ, Spivack B: How many patients complete an adequate trial of donepezil? Alzheimer Dis Assoc Disord 2002; 16: 49-51.
10. Singh G, Thomas SK, Arcona S, Lingala V, Mithal A: Treatment persistency with rivastigmine and donepezil in a large state medicaid program. J Am Geriatr Soc 2005; 53: 1269-1270.
11. Small G, Dubois B: A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin 2007; 23: 2705-2713.
12. Farlow MR, Miller ML, Pejovic V: Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord 2008; 25: 408-422.
13. Dhillon S: Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type. Drugs 2011; 71: 1209-1231.
14. Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R: A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22: 456-467.
15. Guay DR: Rivastigmine transdermal patch: role in the management of Alzheimer's disease. Consult Pharm 2008; 23: 598-609.
16. Shikiar R, Rentz AM: Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues. Value Health 2004; 7: 204-215.
17. Travis SS, Bethea LS, Winn P: Medication administration hassles reported by family caregivers of dependent elderly persons. J Gerontol A Biol Sci Med Sci 2000; 55:M412-M417.
18. Blesa R, Ballard C, Orgogozo JM, Lane R, Thomas SK: Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology 2007; 69:S23-S28.
19. Cummings J, Winblad B: A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Rev Neurother 2007; 7: 1457-1463.
20. Winblad B, Machado JC: Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease. Expert Opin Drug Deliv 2008; 5: 1377-1386.
21. Priano L, Gasco MR, Mauro A: Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging 2006; 23: 357-375.
22. Winblad B, Kawata AK, Beusterien KM, Thomas SK, Wimo A, Lane R, Fillit H, Blesa R: Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007; 22: 485-491.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
24. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
25. Lobo A, Saz P, Marcos G, Dia JL, de la Camara C, Ventura T, Morales Asin F, Fernando Pascual L, Montanes JA, Aznar S: Revalidation and standardization of the cognition mini-exam (first Spanish version of the Mini-Mental Status Examination) in the general geriatric population. Med Clin (Barc) 1999; 112: 767-774.
26. Reisberg B, Ferris SH, de Leon MJ, Crook T: The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-1139.
27. Ruiz MA, Pardo A, Rejas J, Soto J, Villasante F, Aranguren JL: Development and validation of the 'Treatment Satisfaction with Medicines Questionnaire' (SATMED-Q). Value Health 2008; 11: 913-926.
28. Morisky DE, Green LW, Levine DM: Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.
29. Articus K, Baier M, Tracik F, Kuhn F, Preuss UW, Kurz A: A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease. Int J Clin Pract 2011; 65: 790-796.
30. Sevilla C, Jimenez-Caballero PE, Alfonso V: Orally disintegrating donepezil: are the main caregivers of patients with Alzheimer's disease more satisfied with this formulation of donepezil than with the traditional one? Rev Neurol 2009; 49: 451-457.
31. Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, Kressig RW, Downs P, Caputo A, Strohmaier C: Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs 10 cm 2 ) in Alzheimer's disease. Dement Geriatr Cogn Disord 2012; 33: 341-353.
32. Razani J, Kakos B, Orieta-Barbalace C, Wong JT, Casas R, Lu P, Alessi C, Josephson K: Predicting caregiver burden from daily functional abilities of patients with mild dementia. J Am Geriatr Soc 2007; 55: 1415-1420.
33. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE: Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 2008; 3: 211-225.
34. Qaseem A, Snow V, Cross JT Jr, Forciea MA, Hopkins R Jr, Shekelle P, Adelman A, Mehr D, Schellhase K, Campos-Outcalt D, Santaguida P, Owens DK: Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008; 148: 370-378.
35. National Institute for Health and Clinical Excellence: Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease. NICE Technology Appraisal Guidance 217. London, National Institute for Health and Clinical Excellence, 2011.
36. Sevilla C, Jimenez Caballero PE, Alfonso V, Gonzalez-Adalid M: Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients? Dement Geriatr Cogn Disord 2009; 28: 196-205.
37. Emre M, Bernabei R, Blesa R, Bullock R, Cunha L, Daniels H, Dziadulewicz E, Forstl H, Frolich L, Gabryelewicz T, Levin O, Lindesay J, Martinez-Lage P, Monsch A, Tsolaki M, van Laar T: Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease. CNS Neurosci Ther 2010; 16: 246-253.
38. Wentrup A, Oertel WH, Dodel R: Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease. Drug Des Devel Ther 2009; 2: 245-254.
39. Yang LP, Keating GM: Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type. CNS Drugs 2007; 21: 957-965.
40. Molinuevo JL, Arranz FJ: Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer's disease. Expert Rev Neurother 2012; 12: 31-37.
41. Bassil N, Grossberg GT: Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs 2009; 23: 293-307.
42. Karlawish JH, Zbrozek A, Kinosian B, Gregory A, Ferguson A, Low DV, Glick HA: Caregivers' assessments of preference-based quality of life in Alzheimer's disease. Alzheimers Dement 2008; 4: 203-211.